Coming Off a GLP-1: Maintenance, Rebound Weight, and How to Keep It Off

The short version

The single most important thing to know before you stop a GLP-1 is that stopping cold tends to bring the weight back — and that this is the drug wearing off, not you failing. In the pivotal semaglutide trial's extension, participants who came off the drug regained about two-thirds of the weight they had lost within a year, and much of the metabolic improvement reversed alongside it². That's not a reason to feel trapped; it's a reason to treat coming off as a plan rather than an event. For a mother, that plan has real forks in it — a pregnancy you're timing toward, a cost or coverage change, or simply wanting to test whether you can hold the result — and each fork has a smarter and a rougher way through.

This is educational only, not medical advice. But the data here are unusually clear, and knowing them changes how you'd stop.

Why the weight comes back: it's the biology, not willpower

GLP-1 medications work while they're in your system by turning down appetite and slowing gastric emptying. Take the drug away and that appetite suppression goes with it — hunger signals return, and the body's strong drive to defend its prior weight reasserts itself. The trials show this plainly. When semaglutide was stopped and switched to placebo in the STEP 4 design, the group that came off began regaining while the group that continued kept losing³. In the STEP 1 extension, a year after treatment and lifestyle support ended, participants had regained roughly two-thirds of their lost weight². Tirzepatide behaves the same way: in SURMOUNT-4, people randomized to withdraw the drug regained substantial weight, while those who continued it maintained and even extended their loss⁴. Across both molecules, the message is identical — continued treatment maintains the result; stopping reverses much of it. That reframes obesity treatment as ongoing, more like managing blood pressure than finishing a course of antibiotics.

The honest baseline: what you're maintaining

It helps to remember the size of what's on the table. Semaglutide produced about 15% average weight loss in its pivotal trial¹, and the two-year STEP 5 data showed that loss was sustained while treatment continued⁵. So the realistic framing isn't "lose it and be done." It's "reach a weight, then decide how to hold it" — and the evidence says the most reliable way to hold it is some form of continued treatment, not a hard stop.

The maintenance options mothers actually use

"Continue" doesn't have to mean the full dose forever. In practice there are a few paths, and the right one is a clinician conversation, not a rule:

• Stay on a maintenance dose. Many people hold their weight on the dose that got them there, or a step below it. This is the best-supported approach.
• Taper toward the lowest effective dose. Some find a lower dose still holds the result with fewer side effects — the same logic behind microdosing GLP-1s. It's individual, and worth doing under supervision rather than by guesswork.
• Stop deliberately, with scaffolding. If you do come off — for a pregnancy, cost, or personal reasons — go in expecting appetite to return and lean hard on the levers that don't wear off: protein at every meal, resistance training to protect muscle and bone, sleep, and structure. These won't fully match the drug, but they blunt the slope.

The mother-specific reason to plan the exit

For many mothers the trigger to stop isn't weight at all — it's a pregnancy. GLP-1s aren't used in pregnancy, and the stop date is further out than most people assume: the semaglutide label asks you to discontinue at least two months before a planned pregnancy. The "about a week per dose" figure that circulates is the half-life, not the instruction. Tirzepatide's label sets no pre-pregnancy window at all and says instead to stop once a pregnancy is recognized, so conceiving means a planned washout on a date your own clinician writes down, not a rule of thumb. That makes "how do I come off, and what happens when I do" a question you'll likely face on someone else's timeline. Thinking it through in advance — including whether you'll restart afterward — beats improvizing. Our guides on GLP-1s and breastfeeding and birth control on a GLP-1 cover the reproductive-timing pieces that sit next to this decision.

Restarting, and switching, are normal

Coming off isn't a one-way door. If you stop for a pregnancy and want to restart after weaning, that's a routine re-titration, not starting from zero psychologically. And if the question is really "which molecule holds best for me," the maintenance data favor staying on a GLP-1 over stopping either one — our semaglutide vs tirzepatide for mothers and Zepbound vs Wegovy guides compare them, including on how each behaves when you continue versus stop.

How to actually decide

Rebound weight is predictable physiology tracked in the maintenance trial data above, which means it's also plannable. The reliable path is continued treatment at whatever the lowest dose is that holds your result, with a real taper or stop plan when life requires one — and honest support around it. Read the exit terms before you sign up, not after: our review of Henry Meds covers a plan where a multi-month commitment can require paying out the remaining balance to cancel, absent a medical reason a provider signs off on, and Zealthy carries a federal complaint alleging obstructive cancellation practices on top of its low headline price — data worth weighing before you sign anything longer than a month. Peter MD is worth naming as the strictest we found when we checked in August 2026: all sales are final once medication ships, refunds apply only to a defective product reported within 24 hours, and canceling an auto-renewal requires emailing support at least 48 hours ahead, with requests inside that window refused outright — exactly the kind of exit clause you want to have read before a taper plan runs into a subscription you can't back out of.

A prepay plan is its own kind of commitment, worth flagging for the same reason. Nouri is a clean illustration: its advertised $120 is $720 paid six months ahead, against a $175 standing rate — so the discount is real and it is bought with six months you may not want. FitFlow sits at the other end, one price at any dose with no cadence to choose. HealthOn's advertised $189/mo semaglutide and $290/mo tirzepatide are the rate on a 12-month plan paid upfront — real money to have tied up if a taper plan means stopping early, since the standard month-to-month rate isn't published anywhere on the site. Vyora Wellness, by contrast, bills its $299/mo semaglutide and $399/mo tirzepatide on a 4-week subscription with no long prepay required, per its own product page — a shorter leash if your plans change, at a higher headline price. Freya Meds runs the identical pattern to HealthOn: its homepage-advertised "$150 a month" is the twelve-month prepay rate, while the plan you can actually leave anytime runs $297. JustAnswer Weight Loss stacks four separate commitment lengths on top of each other — its own ad-tracking data even treats the deepest, twelve-month prepay tier as the product's "real" price, rather than the roughly $250-a-month rate that applies if you don't prepay a year you might end up not using. Bring your history, your budget, and your pregnancy plans to a clinician, weigh any commitment against the maintenance-trial data above, and build the exit before you need it.